TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Curvebeam AI Ltd. ( (AU:CVB) ) just unveiled an announcement.
CurveBeam AI Limited announced an update regarding the settlement of a $6.5 million placement, where $5.6 million has been received, and the remaining $900,000 is pending due to an offshore transfer delay. The company plans to issue the shares in two tranches, with the first tranche settled and issued, and the second tranche pending receipt of funds. This placement is expected to support the company’s operations and enhance its market positioning in the medical imaging industry.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited (ASX: CVB) is a company that develops, manufactures, and sells specialized medical imaging CT scanners, combined with AI SaaS-based clinical assessment solutions. These products are designed to assist medical practitioners in managing musculoskeletal conditions. The company’s flagship product, HiRise™, offers both weight-bearing and traditional non-weight-bearing CT scans, providing advantages over traditional CT or MRI devices. CurveBeam AI operates with over 70 employees, with its corporate office and AI functions located in Melbourne, Australia, and its global operations headquarters in Hatfield, Pennsylvania, USA.
Average Trading Volume: 301,522
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$39.56M
For a thorough assessment of CVB stock, go to TipRanks’ Stock Analysis page.